WO2016098041A1 - Établissement et utilisation d'une plateforme in vitro pour transition épithélio-mésenchymateuse (emt) - Google Patents

Établissement et utilisation d'une plateforme in vitro pour transition épithélio-mésenchymateuse (emt) Download PDF

Info

Publication number
WO2016098041A1
WO2016098041A1 PCT/IB2015/059724 IB2015059724W WO2016098041A1 WO 2016098041 A1 WO2016098041 A1 WO 2016098041A1 IB 2015059724 W IB2015059724 W IB 2015059724W WO 2016098041 A1 WO2016098041 A1 WO 2016098041A1
Authority
WO
WIPO (PCT)
Prior art keywords
emt
cells
engineered
gene
epithelial
Prior art date
Application number
PCT/IB2015/059724
Other languages
English (en)
Inventor
Mukesh Kumar GANDHARI
Sravanthi RAGAMOUNI
Preethi KULOTHUNGAN
Prithi Rajan
Lakshmipathi KHANDRIKA
Bhupendra Vinayak SHRAVAGE
Jugnu Jain
Sreevatsa Gopinath NATARAJAN
Original Assignee
Saarum Sciences Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saarum Sciences Private Ltd filed Critical Saarum Sciences Private Ltd
Publication of WO2016098041A1 publication Critical patent/WO2016098041A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types

Definitions

  • the present disclosure generally relates to the field of cancer biology. More particularly, the present disclosure relates to products that serve as models for epithelial to mesenchymal transition, methods and uses thereof.
  • EMT Epithelial to Mesenchymal Transition
  • EpH4 cell lines as an EMT platform by expressing ras/V12 ras, and bcl2 in a spontaneously immortalized breast cancer cell line.
  • Use of viral regulators for immortalisation of cells frequently involves inactivation of tumor suppressor genes which might lead to transformation of cell lines. In such cases, there is a possibility that the basic properties of the cell lines might be altered which is not desirable.
  • in vitro EMT model that is derived from healthy and normal human tissue to mimic origin of cancer, to screen novel drugs which perturb and potentially inhibit EMT and also serve as a platform in which specific aspects of the mechanisms of EMT may be studied. It is an object of the present invention to develop an in vitro EMT model/platform based on the use of normal cells and thus be physiologically more relevant to human cancer.
  • the present invention discloses products that serve as in vitro EMT models that can be used in the laboratory at several points in the drug discovery process such as target discovery, validation, screening for small and large molecule drugs alone or in combination with other drugs, or target deconvolution after identifying lead molecules in phenotypic screening in an unbiased manner.
  • Cells demonstrating varying stages of EMT can be used to evaluate the modulatory effects of molecules with different mechanisms of action. Also, the products disclosed in the present invention would aid in identifying novel biomarkers related to cancer and to carry out basic mechanistic studies of generation of CSCs, cancer progression and metastasis.
  • CSCs cancer stem cells
  • this platform can serve to create a process by which enriched population of stem cells or tumour-initiating cells can be obtained and be used as a screen for identification of new molecules or targets that can inhibit CSCs.
  • the present invention also discloses a controlled generation of a platform of cell types representing EMT using specific engineered genes which are known to be involved in the process of EMT.
  • normal human mammary epithelial cells are used as a starting point and EMT is induced by over-expression of an EMT inducer.
  • the present invention uses mammalian cellular regulators such as c-myc (Drissi R et al, 2001, J Biol Chem; 276 (32): 29994-30001) or hTERT (Dimri G et al, 2005; Breast Cancer Res: 7 (4): 171-9) to effect immortalisation instead of a viral oncogene.
  • the epithelial to mesenchymal transition is effected by the over-expression of EMT inducers such as c-met which is a known initiator of EMT in several human epithelial cancers including liver, breast, gastric etc. and is reported to be a driver for the loss of epithelial phenotype and the acquisition of a migratory phenotype (Gaule PB et al, 2014; Expert Opin Ther Targets; 18 (9): 999-1009, Organ SL et al, 2011 ; Ther Adv Med Oncol; 3 (1 Suppl): S7-S19).
  • EMT inducers such as c-met which is a known initiator of EMT in several human epithelial cancers including liver, breast, gastric etc. and is reported to be a driver for the loss of epithelial phenotype and the acquisition of a migratory phenotype (Gaule PB et al, 2014; Expert Opin Ther Targets
  • Exemplary embodiments of the present disclosure are directed towards products that serve as EMT models.
  • the product comprises a plurality of components, wherein the plurality of components are selected from one or more of the following groups: a primary epithelial cell population; a primary fibroblast cell population; a first immortalized stable cell line with epithelial or intermediate phenotype harbouring an engineered immortalizing gene construct; a second immortalized stable cell line with epithelial or intermediate phenotype harbouring an engineered immortalizing gene construct and an engineered assayable marker gene construct; a third immortalized stable cell line with mesenchymal-like or mesenchymal phenotype harbouring an engineered immortalizing gene construct, an engineered assayable marker gene construct and an engineered EMT inducing gene construct; an EMT modulating agent; and an enriched population of cancer stem cells derived from the third immortalized stable cell line.
  • FIG. 1 Other exemplary embodiments of the present subject matter are directed towards methods for making a product that serve as EMT models.
  • the method starts with providing a normal epithelial cell population followed by introducing an engineered immortalizing gene construct into the normal epithelial cell population followed by culturing and selection of the transfected cell population through multiple passages to ensure stable expression of an immortalizing agent to yield a first immortalized stable cell line, wherein the first immortalized stable cell line harbours the engineered immortalizing gene construct and has an epithelial or intermediate phenotype.
  • an engineered assayable marker gene construct into the first immortalized stable cell line to yield a second immortalized stable cell line, wherein the second immortalized stable ceil line harbours the engineered immortalizing gene construct and the engineered assayable marker gene construct and has an epithelial or intermediate phenotype.
  • an engineered EMT inducing gene construct is introduced into the second immortalized stable cell line to yield a third immortalized stable cell line, wherein the third immortalized stable cell line has a mesenchymal-like or mesenchymal phenotype and harbours the engineered immortalizing gene construct, the engineered assayable marker gene construct and the engineered EMT inducing gene construct.
  • the final step comprises of providing a product that serves as an EMT model by assembling a plurality of components, wherein the plurality of components comprise one or more of the following groups: a primary epithelial ceil population; a primary fibroblast cell population; the first immortalized stable cell line; the second immortalized stable cell line; the third immortalized stable cell line; an EMT modulating agent; and an enriched population of cancer stem cells derived from the third immortalized stable cell line.
  • Other exemplary embodiments of the present subject matter are directed towards uses of products that serve as EMT models.
  • the plurality of components disclosed herein can be used for evaluation of drug candidates that target EMT and/or cancer stem cells, evaluation of drug targets in EMT and/or cancer stem cells, evaluation of biomarkers in EMT and/or cancer stem cells, derivation of cancer stem cells and use as a disease model for studying underlying biology of EMT and stem cells.
  • Cells demonstrating varying stages of EMT can be used to evaluate the modulatory effects of molecules with different mechanisms of action.
  • Fig. 1 is a representative phase contrast microscopy image of normal human mammary epithelial cells (HMECs, Left panel) and normal human mammary fibroblasts (Right panel) grown in two dimensional culture at passage number 2. Objective magnification was 10X. This figure is in accordance with a particular non limiting exemplary embodiment of the present disclosure.
  • Fig. 2 is an image representing expression of epithelial and mesenchymal markers in the isolated human mammary epithelial and fibroblast cells determined by PCR.
  • PCR products denoting expression of the genes Mucin 1 (171 bp, Lanes 1,2), Desmoglein 2 (278 bp, Lanes 3,4), Slug (181 bp, Lanes 6,7), Snail (248 bp, Lanes 8,9), Twist 1 (200 bp, Lanes 11,12), and Fibronectin (382 bp, Lanes 13,14) are shown.
  • GAPDH 115 bp, Lane 15
  • Lanes 5 and 10 represent the DNA ladder used to determine the size of the PCR products.
  • the letter ⁇ ' denotes epithelial cells and 'F' denotes fibroblasts as the source of the template. This figure is in accordance with a particular non limiting exemplary embodiment of the present disclosure.
  • FIG. 3 represents immunofluorescence images of HMECs. Representative images are at passage 2 showing staining for epithelial markers EpCAM (Panel A) and Cytokeratin 8/18 (CK8/18, Panel B). The cells do not have any detectable staining for the mesenchymal marker Vimentin (Panel C). All cells were also stained for DAPI, a nuclear marker, to visualize the number of cells and nuclear vs. cytosolic localization. Objective magnification was 60X. This figure is in accordance with a particular non limiting exemplary embodiment of the present disclosure.
  • Fig. 4 represents immunofluorescence staining of normal human mammary fibroblast cells. Representative images are at passage 2 demonstrating lack of staining with the epithelial marker EpCAM (Panel A). Cells stained for the mesenchymal markers, a-Smooth Muscle Actin (a-SMA, Panel B) and Vimentin (Panel C) show positive staining for both. All cells were also stained for DAPI, a nuclear marker, to visualize the number of cells and localize the nuclear vs cytosolic staining. Objective magnification was 60X. This figure is in accordance with a particular non limiting exemplary embodiment of the present disclosure.
  • Fig. 5 is a graphic representation of expression of epithelial and mesenchymal markers in c-myc immortalized stable cell line as determined by Quantitative Real-Time PCR.
  • Epithelial markers used were Mucin 1 and Desmoglein 2, while the mesenchymal markers used were Snail and Fibronectin.
  • the open bars represent HMECs at passage 3, and the filled bars represent passage 10 of HMECs transfected with c-myc. Bars denote average and SD of the assay done in triplicate. This figure is in accordance with a particular non limiting exemplary embodiment of the present disclosure.
  • Fig. 6 represents immunofluorescence images of HMECs transfected with c-myc. Representative images are at passage 10 showing cells stained with EpCAM (Left panel) and Vimentin (Right panel). All cells were stained with DAPI to visualize the number of cells and localization of cytosolic staining. Objective magnification was 20X. This figure is in accordance with a particular non limiting exemplary embodiment of the present disclosure.
  • Fig. 7 is a graphic representation of expression of epithelial and mesenchymal markers in HMECs transfected with c-myc and E-Cadherin-GFP, as determined by Quantitative Real- Time PCR.
  • Epithelial markers used were Mucin 1 and Desmoglein 2, while the mesenchymal markers used were Snail and Fibronectin.
  • the open bars represent HMECs at passage 3
  • filled bars represent HMECs transfected with c-Myc and the grey shaded bars represent double transfected cells. Both the c-myc and double transfected cells were from passage 10. Bars denote average and SD of the assay done in triplicate. This figure is in accordance with a particular non limiting exemplary embodiment of the present disclosure.
  • Fig. 8 represents immunofluorescence images of double transfected cells at passage 10.
  • EpCAM Panel A
  • Vimentin Porel B
  • All cells were stained with DAPI to visualize the nucleus and hence the number of cells.
  • Objective magnification was 20X. This figure is in accordance with a particular non limiting exemplary embodiment of the present disclosure.
  • Fig. 9 is a representative phase contrast microscopy image of HMECs triple transfected with c-Myc, E-Cadherin-GFP, and c-Met-tomato maintained in two dimensional culture at passage number 10.
  • Objective magnification is at 10X. This figure is in accordance with a particular non limiting exemplary embodiment of the present disclosure.
  • Fig. 10 is a graphical representation of the expression of epithelial and mesenchymal markers in HMECs triple transfected with c-myc, E-Cadherin-GFP and c-Met-tomato, as determined by Quantitative Real-Time PCR.
  • Epithelial markers used were Mucin 1 and Desmoglein 2, while the mesenchymal markers used were Snail and Fibronectin.
  • the open bars represent HMECs at passage 3
  • filled bars represent HMECs transfected with c-myc alone and the grey shaded bars represent triple transfected cells. Both the c-myc and triple transfected cells were obtained from passage 10. Bars denote average and SD of the assay done in triplicate. This figure is in accordance with a particular non limiting exemplary embodiment of the present disclosure.
  • FIG. 11 is an image showing immunofluorescence staining of HMECs triple transfected with c-Myc, E-Cadherin-GFP, and c-Met, at passage 10. Representative images showing staining for the epithelial marker EpCAM (Panel A) and for the mesenchymal marker Vimentin (Panel B). Cells were also stained with DAPI to visualize the nucleus and cytosolic staining. Objective magnification was 20X. This figure is in accordance with a particular non limiting exemplary embodiment of the present disclosure.
  • Fig. 12 represents a fluorescence microscopy image of triple transfected HMECs representing the expression of red coloured tomato reporter gene (right panel). Phase contrast microscopy image of the cells is depicted in the left panel. Images are taken with 20X objective. This figure is in accordance with a particular non limiting exemplary embodiment of the present disclosure.
  • Fig. 13 represents images of ⁇ -galactosidase assay to determine senescence in the different cell types developed.
  • HMECs at passage 6 show intense blue colour in groups of cells indicated by arrows.
  • C-myc Panel B
  • C-myc and E-Cadherin-GFP Panel C
  • C-Myc, E-Cadherin-GFP and C-Met-tomato (Panel D) transfected cells were negative for the ⁇ -galactosidase assay. All the three transfected cell types used in this assay were from passage 10.
  • Objective magnification was 10X. This figure is in accordance with a particular non limiting exemplary embodiment of the present disclosure.
  • Fig. 14 is a graphical representation of Real-Time quantitative PCR to determine the expression levels of hTERT.
  • HMECs at passage 3 were used in this assay while the three transfected cell lines were from passage 10.
  • Relative fluorescence units were normalized to HMECs set at 100%.
  • Graph denotes the average and SD of the expression levels from an assay done in triplicate. This figure is in accordance with a particular non limiting exemplary embodiment of the present disclosure.
  • Fig. 15 shows images representing sphere forming assay in non-adherent plates and serum-free culture conditions. 100,000 cells were seeded and allowed to form spheres for 7 days. HMECs (Panel A) failed to form spheres and remained dispersed and slowly died, while cells transfected with c-myc (Panel B), c-myc + E-Cadherin-GFP (Panel C), and with c-myc + E-Cadherin-GFP + c-met-tomato (Panel D) formed spheres, albeit at different rates and sizes. HMECs were at passage 3 while the other three cell lines were at passage 10. Images were taken with 10X objective. This figure is in accordance with a particular non limiting exemplary embodiment of the present disclosure.
  • Fig. 16 shows images representing colony forming assay in soft agar. Cells were seeded and allowed to form colonies for 40 days. Primary epithelial cells (Panel A) failed to form colonies, while cells transfected with c-myc + E-Cadherin-GFP (Panel B), and with c-myc + E-Cadherin-GFP + c-met-tomato (Panel C) formed colonies of different sizes. Images were taken with 10X objective of phase contrast microscope. This figure is in accordance with a particular non limiting exemplary embodiment of the present disclosure. [034] Fig.
  • FIG. 17 is a graphical representation of the number of colonies formed in soft agar by the different cell types, based on the size of the colonies enumerated on Day 40.
  • the graphs represent the average and SD from duplicate wells of a representative experiment. This figure is in accordance with a particular non limiting exemplary embodiment of the present disclosure.
  • Fig. 18 represents a flow cytometric detection of cancer stem cells (CSCs) by CD44 and CD24 antibody staining.
  • HMECs Panel A
  • c-myc single transfected cells Panel B
  • triple transfected cells Panel C
  • Stained cells were gated for CD44+ and CD24- population and sorted in a FACS Canto II (BD Biosciences).
  • the bottom right quadrant represents the CD44+/CD24- cells reported to be cancer stem cells.
  • Fig. 19 is a graphical representation of migration potential of the different cell types as determined by wound healing assay.
  • the panels correspond to A) HMECs, B) HMECs transfected with c-Myc, C) HMECs transfected with c-Myc and E-Cadherin-GFP, and D) HMECs transfected with c-Myc, E-Cadherin-GFP, and c-Met-Tomato.
  • the percentage of open wound area was calculated based on the density of the cells present in the scratch, when compared to the 0 hour of HMECs which was set at 100%.
  • the graphs are average and SD of triplicate wells from a representative experiment of two independent experiments. This figure is in accordance with a particular non limiting exemplary embodiment of the present disclosure.
  • normal used with reference to epithelial cells in the present disclosure refers to non-cancerous healthy tissue.
  • the tissues used in these studies were obtained from young healthy females who did not have cancer.
  • the epithelial and fibroblast cells isolated from such non-diseased healthy tissue samples are considered normal.
  • tissue refers to any biological fluid or tissue.
  • a sample may be a tissue containing epithelial cells, either non-diseased or malignant cells.
  • useful biological samples include, without limitation, surgical material from solid tumours, biopsy, bone marrow, blood, saliva, sputum, urine, cerebrospinal fluid, cervical smear and other cellular exudates from a person. Such samples may further be diluted with sterile saline, PBS, cell culture medium, or a pH-balanced physiologically acceptable solution prior to grossing and processing.
  • Immortalized stable cell line used in the present disclosure encompasses primary cells modified either through introduction of a gene such as the catalytic subunit of the human telomerase enzyme (hTERT) encoded in a vector, or spontaneously due to acquisition of genetic changes, to become a continuously growing or 'immortalized cell line's. Unlike normal cells, immortalized cells do not undergo senescence typically observed at passage 5-7. Such immortalized cells, able to be passaged beyond passage 7 are considered a stable cell line. Examples of immortalizing genes include hTERT, myc, bmi-1 and those described in international patent publication numbers EP2611902 and references incorporated therein.
  • engineered immortalizing gene construct used in the present disclosure refers to gene(s) cloned into vectors using standard recombinant DNA techniques to create plasmids that can be introduced into cells to immortalize them and generate stable cell lines.
  • engineered immortalizing gene constructs include a vector (viral or others) coding for any of hTERT, bmi-1, myc genes and those described in international patent publication numbers EP2611902, US8642834, US7998688 and the references incorporated therein.
  • engineered assayable marker gene construct refers to genes/promoters that can serve as reporters of a change in phenotype. These genes/promoters are engineered or cloned into vectors using standard recombinant DNA techniques to create gene constructs or plasmids expressing the markers fused to a fluorescent gene that when introduced into cells can be used for a quantitative assessment of change in phenotype.
  • assayable markers include but are not limited to E-cadherin, cytokeratin 8, cytokeratin 18, as epithelial markers and N-cadherin, vimentin, twist, snail, fibronectin, zeb as mesenchymal markers and those cited in international patent publication numbers incorporated herein by reference (US7998688, WO2010011642, US7951549) and the references incorporated therein.
  • Reporter genes that can be fused with such assayable markers include but are not limited to fluorescent GFP, RFP, YFP, BFP, luminescent markers such as luciferase, colorimetric and others included herein by reference from international patent publication number, US7951549 and the references incorporated therein.
  • the term 'engineered EMT inducing gene construct' used in the present disclosure refers to genes or promoters whose over- or under-expression can lead to EMT, that are cloned in vectors using standard recombinant DNA techniques. These vectors can be introduced into cells to effect EMT in those cells. Examples of genes and promoters include c-Met, Twist, Snail, Slug, CDH1 promoter, Src kinase and those described in International Patent Publication Numbers incorporated herein by reference (US7951549, US20110191868, WO2010011642)
  • the term 'cancer stem cells' includes cells that have the property of self-renewal as well as initiating, progressing and maintaining tumours. These cells are generated during the process of EMT and may also be termed stem cells or progenitor cells, incorporated by references herein (CA2656548, WO2013131000). CSCs or SCs have been shown to be more resistant to chemo- and radiation therapies (Kwiatkowska-Borowczyk et al Contemp Oncol (Pozn) 2015; 19: A52-A59, Fillmore and Kuperement, Breast Cancer Res, 2008, 10: R25).
  • epithelial cancer used in the present disclosure covers an epithelial cell cancer selected from the group consisting of carcinomas that derive from epithelial cell types.
  • epithelial cell cancers include breast, colorectal, ovarian, lung, pancreatic, kidney, prostate and gastric cancer, among others.
  • aggressive cancer subtypes include basal cancer or lobular cancer, e.g., certain aggressive breast cancers.
  • the term 'mesenchymal cells or phenotype' encompasses cells that are loosely associated and that have lost the tight junctions observed in epithelial cells, express markers including FN, snail, slug, vimentin, aSMA, zebl, N-cadherin, CDH1 methylation, FOXC2, twist demonstrate increased motility and invasiveness (Yausch et al Clin Cancer Res, 2005 11 ; 8686, Kim et al Experimental & Molecular Medicine (2015) 47, el37).
  • Additional mesenchymal cell biomarkers include, fibrillin- 1, fibrillin-2, collagen alpha2(IV), collagen alpha2(V), LOXL1, nidogen, Cl l or f9, tenascin, tubulin alpha-3, and epimorphin.
  • Basal-type breast cancers that are known to be the most aggressive with high rate of recurrence and poor overall survival display more mesenchymal phenotype compared with the luminal cancers (Kim et al Experimental & Molecular Medicine (2015) 47, el37).
  • the term "Intermediate phenotype" used in the present disclosure refers to the following:
  • the EMT process is a continuum comprising many steps and cellular phenotypes that capture multiple discrete stages along the way of epithelial cells becoming mesenchymal cells.
  • These phenotypes may be designated as 'intermediate or mixed phenotypes' since they exhibit some characteristics of epithelial cells and some of mesenchymal cells. Examples of such 'intermediate phenotypes' may range from mostly epithelial-like cells that demonstrate expression of some epithelial markers but not all, little to no expression of mesenchymal proteins but show altered morphology compared to normal epithelial cells.
  • Intermediate phenotypes may also include mesenchymal-like cells that have acquired the expression of mesenchymal proteins whilst also expressing low levels of epithelial proteins, exhibit increased motility in migration and invasion assays, but not be able to form colonies in soft agar.
  • Such intermediate phenotypes are valuable in identifying drug targets or molecules that can modulate early stages of EMT and cancer-promoting activities of mesenchymal cells.
  • co-expression of CK8/18 and EpCAM with Vimentin and aSMA may be termed an intermediate phenotype.
  • evaluation used in the present disclosure includes any screening activity to identify, validate, repurpose, prioritize, rank order a 'drug candidate', a drug target, a biomarker in a comparative manner to select promising candidates or optimize leads as examplified incorporated herein by reference (US8642834, US7998688, US7951549, US20110191868)
  • the term 'drug candidate' encompasses a compound, an antibody, a peptide, a protein or a RNA that can modulate the expression and/or activity of a molecule or complex of interest (the "target") with potential to be used as a therapeutic.
  • a compound that inhibits one or more activities of a target or a cell in the presence of the compound, or as a consequence of its use, as compared with in the absence of the compound, and/or if the level or amount of the target or cell function is modulated in the presence of the compound, or as a consequence of its use, as compared with in the absence of the compound may be considered as a drug candidate.
  • drug candidate molecules act directly on their target in that they physically interact with it.
  • compounds act indirectly, e.g., by inhibiting a second molecule that is needed for synthesis or activity of the target or cells.
  • biomarker is defined as a laboratory measurement that reflects the activity of a disease process as incorporated herein by reference (Katz NeuroRx. 2004; 1 : 189-195). Examples of such markers include positron emission tomographic (PET) scanning of cancers wherein markers quantitatively correlate (either directly or inversely) with disease progression.
  • PET positron emission tomographic
  • a gene signature of EMT or FOXC2 may be used to diagnose, monitor and/or tailor treatment as shown in international patents incorporated herein by reference (US20120302572, US8088590, CA2601157, US20120159655, WO2012116248).
  • the term "disease model" used in the present disclosure refers to an in vitro or in vivo model system that is experimentally created or induced with pathological processes sufficiently similar to those in human disease that is used to understand the origin and progression of the disease, to monitor and treat it.
  • the panel of epithelial and mesenchymal cells isolated from normal breast tissue and the ones created herein using engineered constructs can be used as model to understand the biology of cancer as a disease and EMT as a process leading up to the disease. The insights gained from such fundamental understanding would be useful in blocking or reversing the EMT process in the lab resulting in more effective treatments in the clinic.
  • a product that serves as an EMT model comprises a plurality of components, wherein the plurality of components are selected from one or more of the following groups: a primary epithelial cell population; a primary fibroblast cell population; a first immortalized stable cell line with epithelial or intermediate phenotype harbouring an engineered immortalizing gene construct; a second immortalized stable cell line with epithelial or intermediate phenotype harbouring an engineered immortalizing gene construct and an engineered assayable marker gene construct; a third immortalized stable cell line with mesenchymal-like or mesenchymal phenotype harbouring an engineered immortalizing gene construct, an engineered assayable marker gene construct and an engineered EMT inducing gene construct; an EMT modulating agent; and an enriched population of cancer stem cells derived from the third immortalized stable cell line.
  • a method for making a product that serves as an EMT model starts with providing a normal epithelial cell population followed by introducing an engineered immortalizing gene construct into the normal epithelial cell population followed by culturing and selection of the transfected cell population through multiple passages to ensure stable expression of an immortalizing agent to yield a first immortalized stable cell line, wherein the first immortalized stable ceil line harbours the engineered immortalizing gene construct and has an epithelial or intermediate phenotype.
  • an engineered assayable marker gene construct into the first immortalized stable cell line to yield a second immortalized stable cell line, wherein the second immortalized stable ceil line harbours the engineered immortalizing gene construct and the engineered assayable marker gene construct and has an epithelial or intermediate phenotype.
  • an engineered EMT inducing gene construct was introduced into the second immortalized stable cell line to yield a third immortalized stable ceil line, wherein the third immortalized stable ceil line has a mesenchymal-like or mesenchymal phenotype and harbours the engineered immortalizing gene construct, the engineered assayable marker gene construct and the engineered EMT inducing gene construct.
  • the final step comprises of providing a product that serves as an EMT model by assembling a plurality of components, wherein the plurality of components comprise one or more of the following groups: a primary epithelial cell population; a primary fibroblast cell population; the first immortalized stable cell line; the second immortalized stable cell line; the third immortalized stable cell line; an EMT modulating agent; and an enriched population of cancer stem cells derived from the third immortalized stable ceil line.
  • the plurality of components disclosed herein can be used for evaluation of drug candidates that target EMT and/or cancer stem cells, evaluation of drug targets in EMT and/or cancer stem cells, evaluation of a biomarkers in EMT and/or cancer stem cells, derivation of cancer stem cells and use as a disease model for studying underlying biology of EMT and CSCs.
  • the plurality of components disclosed herein can be used for evaluation of biomarkers, targets and/or drug candidates for triple negative breast cancer embodied by the triple transfected cell line. It has been reported that EMT induced by c-Met causes triple negative breast cancer (Minuti and Landi , 2015).
  • the immortalized stable cell lines are obtained from human epithelial cells.
  • the immortalized stable cells can be obtained from the epithelial cells of other mammalian species also without limiting the scope of the present disclosure.
  • the immortalized stable cell lines are obtained from mammary epithelial cells.
  • the immortalized stable cells can be obtained from the epithelial cells of other organs also without limiting the scope of the present disclosure.
  • the immortalized stable cell lines are obtained from normal epithelial cells.
  • the immortalized stable cells can also be obtained from benign tumour cells of epithelial phenotype without limiting the scope of the present disclosure.
  • Epithelial cells for use in composition and methods of the invention and/or to which methods of the invention may be applied, can be obtained from any of a wide variety of sources or, in the case of certain in vivo applications, may be present in a variety of tissues or organs.
  • the cells may be primary cells, cells of a cell line, untransformed cells, transformed cells, genetically modified cells, or non-genetically modified cells, in various embodiments.
  • cells can be obtained from a human or other mammalian subject, from discarded surgical or cellular samples from a subject, or from a propagated cell line.
  • the engineered immortalizing gene construct is designed to overexpress an immortalizing agent.
  • c-myc, h-TERT and/or Bmil are used as immortalizing agents though any other cellular regulator that is known in the art for immortalizing epithelial cells can be used without limiting the scope of the present disclosure.
  • the present invention discloses use of mammalian cellular regulator genes for immortalization instead of viral oncogenes that are generally used for immortalisation. This prevents the undesirable effect of transformation of cell lines that often occur when viral oncogenes are used for immortalisation.
  • the engineered assayable marker gene construct is designed to overexpress an assayable marker.
  • the engineered assayable marker gene construct was designed to overexpress an assayable marker and a reporter.
  • E-Cadherin, EpCAM, cytokeratin, N-Cadherin and/or Vimentin are used as the assayable markers though any other assayable marker known in the art for detecting and characterising EMT can be used without limiting the scope of the present disclosure.
  • GFP, BFP, YFP and RFP are used as the reporters though any other fluorescent reporter or luminescent reporter such as iuciferase or colorimetric reporter that is known in the art for assaying the expression of the gene of interest can be used without limiting the scope of the present disclosure.
  • the engineered EMT inducing gene construct is designed to overexpress an EMT inducer.
  • the engineered EMT inducing gene construct was designed to overexpress an EMT inducer and a reporter.
  • c-Met, Twist, ras, slug, zeb and/or snail are used as EMT inducers though any other EMT inducer that is known in the art capable of inducing EMT can be used without limiting the scope of the present disclosure.
  • GFP, BFP, OFP, YFP and RFP are used as the reporters though any other fluorescent reporter or luminescent reporter such as iuciferase or coiorimetric reporter that is known in the art for assaying the expression of the gene of interest can be used without limiting the scope of the present disclosure.
  • the EMT modulating agent that either induces or inhibits the process of EMT is an engineered gene construct, RNA, a protein, a synthetic molecule and/or an antibody.
  • the engineered gene construct used as the EMT modulating agent is designed to overexpress an EMT inducing gene in a transient manner.
  • the engineered gene construct used as the EMT modulating agent is designed to overexpress an EMT inducing gene and a reporter in a transient manner.
  • the protein used as the EMT modulating agent is an EMT inducer.
  • c-Met, Twist, ras, slug, zeb and/or snail gene are used as the EMT inducers though any other EMT inducer that is known in the art to be capable of inducing EMT can be used without limiting the scope of the present disclosure.
  • GFP, BFP, YFP and RFP are used as reporters though any other fluorescent or luminescent reporter such as Iuciferase or coiorimetric reporter that is known in the art for assaying the expression of the gene of interest can be used without limiting the scope of the present disclosure.
  • engineered gene constructs include cMet, zeb, snail, slug, twist, ras and those described in International Patent Publication Nos EP2611902, US20120302572 and publications (Minuti and Landi, Ann Transl Med. 2015: 3: 181, Kim et al Experimental & Molecular Medicine (2015) 47, el 37) incorporated herein by reference.
  • RNA interference may be employed to inhibit expression in eukaryotic cells, e.g., vertebrate cells, in a variety of ways as known in the art.
  • RNAi agent encompasses nucleic acids that can be used to achieve RNAi in eukaryotic cells.
  • exemplary RNAi agents are short interfering RNA (siRNA) and short hairpin RNA (shRNA).
  • siRNAs typically comprise two separate nucleic acid strands that are hybridized to each other to form a duplex.
  • RNAi agents can be synthesized in vitro, e.g., using standard nucleic acid synthesis techniques or by cleavage of a longer dsRNA, e.g., by an RNase III or RNase Ill-like enzyme such as Dicer.
  • RNAi agents also include microRNA (miRNA) and miRNA precursors.
  • miRNA microRNA
  • miRNA precursor encompasses naturally occurring and artificially designed nucleic acids that function in an analogous manner to naturally occurring miRNAs.
  • an RNAi agent is a vector that comprises a template for transcription of an siRNA (e.g., as two separate strands that can hybridize to each other), shRNA, or microRNA precursor.
  • Such vectors can be used to introduce the template into vertebrate cells, e.g., mammalian cells, and result in transient or stable expression of the siRNA, shRNA, or miRNA precursor.
  • RNA include miRNA, siRNA, shRNA and those described in International Patent Publication Nos EP2611902 and publications that are incorporated herein by reference.
  • proteins such as EGF, TGFb, HGF, Wnt, MSP, Hedgehog, TNF-alpha, IL4, HB-EGF, amphiregulin, betacellulin, epiregulin, epigen, oncostatin-M, IL-13 were used as EMT modulating agents and those described in International Patent Publication Nos (EP2611902, US7998688, US7951549), and publications that are incorporated herein by reference. Proteins may be naturally occurring e..g TGFb polypeptide (TGFbl, TGFb2, or TGFb3) or be synthesized as peptides. Any other protein that is known in the art is which is capable of modulating EMT can be used without limiting the scope of the present disclosure.
  • TGF-beta inhibitors A83-01 and SB435142 were used as EMT modulating agents though any other synthetic molecule that are known in the art which can modulate EMT can be used without limiting the scope of the present disclosure.
  • synthetic molecules described in International Patent Publication Nos EP2611902, US20140010789, and publications are incorporated herein by reference.
  • PCT/US2008/011648 discloses small molecules reported to activate TGF beta signaling.
  • the antibodies that are used as EMT modulating agents can originate from a mammalian or avian species, e.g., human, rodent (e.g., mouse, rabbit), goat, chicken, etc., or can be generated ex vivo using a technique such as phage display.
  • Such antibodies include members of the various immunoglobulin classes, e.g., IgG, IgM, IgA, IgD, IgE, or subclasses thereof such as IgGl, IgG2, etc., and, in various embodiments, encompasses antibody fragments or molecules that retains an antigen binding site and encompasses recombinant molecules comprising one or more variable domains.
  • antibody examples include OnartuzuMab and those described in International Patent Publication Nos EP2611902 and publications (Minuti and Landi, Ann Transl Med. 2015: 3: 181) that are incorporated herein by reference. Also any other antibody that is known in the art to modulate EMT can be used without limiting the scope of the present disclosure.
  • inventive compositions and methods may be employed singly or together with modulators of multiple signaling pathways such as the Notch pathway, Hedgehog pathway, signaling via tyrosine kinase receptors such as Met, FGF, IGF, EGF, HGF, VEGF, and/or PDGF receptor family members, the NFkB pathway, hypoxia inducible factor (HIF) pathway, and/or microRNA regulatory pathways.
  • the EMT modulating agents may modulate or perturb EMT, stimulate MET, or inhibit the growth of mesenchymal-like cells as shown in the reference US7951549 that is incorporated herein.
  • breast cancer stem cells may be defined as the subpopulation of breast cells staining positively with CD44 antigen but with low to no expression of CD24 in flow cytometry assays (Sheridan et al, Breast Cancer Research 2006, 8:R59 and references cited therein).
  • Expression levels of proinvasive genes IL-la, IL-6, IL-8, and urokinase plasminogen activator [UPA] have been reported to be higher in cell lines with a significant CD44 + /CD24 " population than in other cell lines, and thus can be used to identify strategies to overcome invasive properties of CSCs.
  • the assayable marker gene construct may be a promoter-reporter construct used to measure promoter activity in cells.
  • the activity of an epithelial biomarker gene promoter is assessed by inclusion of an epithelial biomarker gene promoter-reporter gene construct into HMECs such that said promoter activity can be monitored by reporter gene expression level or activity.
  • the epithelial biomarker gene promoter-reporter gene construct may be an E-cadherin promoter-GFP construct.
  • the promoter-reporter gene construct may be permanently incorporated into the HMECs as a stable engineered cell line, or may be transiently expressed.
  • promoter-gene-reporter gene constructs may also be employed in order to monitor several biomarkers simultaneously, e.g. an E-cadherin promoter-GFP construct and a cMet-tdTomato construct, in order to, for example, monitor simultaneous repression of the E-cadherin gene and induction of the cMet gene during EMT (US7951549) and references incorporated therein).
  • an inducible promoter is a tetracycline (tet)-responsive promoter.
  • tet tetracycline
  • Fluorescent or luminescent reporters can also be used in vivo to track tumour cell growth and metastasis (US7951549).
  • the engineered EMT inducing gene constructs may comprise constitutively active promoters and hence activity of the EMT inducing gene.
  • engineered EMT inducing gene constructs may comprise inducible promoters and hence inducible on-off activity of the EMT inducing gene (US7998688).
  • the EMT inducing gene constructs may comprise constitutively active promoter and EMT inducing gene but the construct may be used to induce EMT in a transient or metastable manner without deriving stable cell lines using antibiotic selection (US20120302572, US8642834, EP2611902).
  • the plurality of components disclosed herein can be used for different purposes such as evaluation of a drug candidate targeting EMT and cancer stem cells, evaluation of a drug target targeting EMT and cancer stem cells, evaluation of biomarkers targeting EMT and cancer stem cells, derivation of cancer stem cells and use as a disease model for studying underlying biology of EMT, triple negative breast cancer and cancer stem cells.
  • the term 'drug candidate' encompasses a compound, an antibody, a peptide, a protein or a RNA that can modulate the expression and/or activity of a molecule or complex of interest (the "target") with potential to be used as a therapeutic.
  • a compound that inhibits activity of a target or a cell in the presence of the compound, or as a consequence of its use, as compared with in the absence of the compound, and/or if the level or amount of the target or cell function is modulated in the presence of the compound, or as a consequence of its use, as compared with in the absence of the compound may be considered as a drug candidate.
  • drug candidate molecules act directly on their target in that they physically interact with it.
  • compounds act indirectly.
  • This platform is particularly suited for conducting phenotypic screening to identify drug candidates that demonstrate desired phenotype without knowing their target. The target may be deconvoluted later using mechanism-of-action studies.
  • Drug candidate examples that are expected to be identified are incorporated herein by reference (EP2611902, US8642834, US7998688, US7951549, US20110191868, CA2656548, US20130158087, US20100088775, US20110033471, US20120156216, US20120220546, WO2013123588, EP2569335, Li et al / Biomol Screen 2011 16: 141)
  • Methods of inhibiting encompass methods that result in a decreased amount of a target or cellular function and methods that interfere with one or more functions of a target or cell.
  • a variety of methods useful for inhibiting or interfering with expression can be applied in embodiments of the present invention.
  • the present invention provides compositions and methods useful for modulating the epithelial-mesenchymal transition.
  • the invention provides a composition comprising normal cells or engineered cell lines selected from each of at least two of the following groups: (a) normal human mammary epithelial or fibroblast cells that can serve as control; (b) engineered immortalized stable cell line derived from normal mammary epithelial cells; (c) engineered immortalized stable cell line expressing a gene that can serve as a marker of E to M transition; and (d) engineered immortalized stable cell line expressing a gene that can serve as a marker of E to M transition in which EMT has been induced by an oncogene relevant to breast cancer including triple negative breast cancer and many human cancers of epithelial origin.
  • the composition comprises at least one engineered cell line from each of these three groups: (a) engineered immortalized stable cell line derived from normal mammary epithelial cells; (b) engineered immortalized stable cell line expressing a gene that can serve as a marker of E to M transition; and (c) engineered immortalized stable cell line expressing a gene that can serve as a marker of E to M transition in which EMT has been further induced by an oncogene involved in a variety of human cancers of epithelial origin.
  • the invention provides composition/methods comprising one control and one mesenchymal cell type to identify targets, drug candidates or markers to modulate EMT.
  • Control could be primary epithelial cells as the normal unmanipulated non-cancerous cells compared to the triple transfected cells that have acquired migratory, sphere-formation and CSC properties.
  • the triple transfected cells are triple negative breast cancer.
  • benign tumours of epithelial origin such as phylloids may be compared with triple transfected stable line to delineate changes resulting in uncontrolled proliferation to invasiveness to tumour initiation.
  • the normal fibroblast cells can be used as a control for normal unmanipulated non-cancerous but mesenchymal cells but which don't demonstrate the migratory, anchorage independent phenotype of triple transfected cells.
  • hTERT immortalized cells can be used as a control to compare to triple transfected cells that have acquired migratory, sphere-formation and CSC properties.
  • the double transfected cells may be used as a control for triple transfected cells whereby the double transfected cells have intermediate phenotype of enhanced migration and sphere formation but are not able to form colonies in soft agar as the triple transfected are able to. This may identify the penultimate changes required for the mesenchymal-like double transfected cells to transform into completely mesenchymal cells generating CSCs.
  • normal human mammary epithelial cells are immortalized using cellular regulators such as c-myc or hTERT to effect immortalisation.
  • the stable cell lines obtained after immortalization were transfected with E-Cadherin-GFP, wherein E-Cadherin served as the assayable marker and GFP served as the reporter. This is followed by further transfection of the immortalised stable cell lines with an EMT inducing gene construct.
  • E-Cadherin-GFP wherein E-Cadherin served as the assayable marker and GFP served as the reporter.
  • c-Met-RFP was used, wherein c-Met served as the EMT inducer and GFP served as the reporter.
  • tdTomato fluorescent protein was used as the reporter along with c-Met.
  • the tissue was placed in a sterile container containing DMEM media and transported to the lab.
  • the epithelial tissue was collected by scraping off the stroma, surrounding connective tissue using sterile scalpel, forceps and blades.
  • the epithelial tissue was collected into a sterile plastic 100mm culture dish and minced into finer pieces (l-3mm2) for proper digestion, collected into a 50ml tube test tube containing collagenase enzyme (100 U/ml) and DNase enzyme (2U/ml) in DMEM media.
  • the tissue with the enzyme solution was incubated for overnight digestion (Day 1) in shaking water bath @ 370C/ 80rpm/10-12hrs. The following day of digestion the tubes were spun @ 600g (1800 rpm); 5 min; at room temperature. The supernatant fat and enzyme solution from the tubes were discarded.
  • Two ml media was added to the tubes with pellet and triturated gently using 10 ml serological pipettes; 5ml and finally with pi 000 pipette
  • the tissue was observed for organoid like structures with a drop onto a sterile slide under microscope. Ensuring the organoids are free of any stromal tissue, the tissue was plated at a density of 40-80 organoids/100 mm dish. For complete assurance of stroma free ductal structures the tissue was digested one more time in a fresh digestion solution overnight at 370C. After the digestion was complete, the pellet containing 10-25 organoids was plated in 35mm dish in DMEM-F12(1 :1) media supplemented with 4% FCS, EGF (20ng/ml), Insulin (lOug/ml), Hydrocortisone (0. lug/ml), Bovine pituitary extract (35ug/ml) & N2 (IX).
  • HMECs Human mammary epithelial cultures
  • Normal breast tissue was dissected in a sterile manner as mentioned above.
  • the stromal part was separated and digested with 100 U/ml Collagenase and lU/ml DNase I for overnight at 37°C water bath.
  • cells were counted using haemocytometer and plated onto T-75 flask in DMEM/F12 containing 10% FBS medium.
  • Confluent cells from T-75 flask were frozen and characterized for cell surface markers, such as Smooth muscle actin and Vimentin.
  • Established fibroblast cultures were used for generating conditioned medium for culturing epithelial cells. For this, fibroblasts were grown to 90% confluency and fresh Serum-free media was added for 72 h. This was collected and concentrated using Amicon filters. Aliquots of 1 ml were stored at -20°C until further use. After several trials and conditions, 5-10% condition medium was optimized for culturing transfected cells.
  • the cells were plated onto sterile coverslip in 12 well dish. 5000 cells were added onto each coverslip and incubated at 37°C for 30min for cell attachment before lml media was added. Once the cells were ready for fixation, the spent media was removed and cells were fixed with 4% paraformaldehyde and incubated for 20min at room temperature.
  • Cells were permeabilized with 0.1% Triton x-100 for 15min, blocked with 1% BSA in PBS then washed 3 times with PBS at room temperature. The cells were incubated with primary antibody (dissolved in blocking buffer) anti-E-cadherin, anti-cytokeratin 8/18, anti-vimentin, anti-aSMA for overnight at 4°C in dark. Later, cells were washed 3 times with PBS and incubated with secondary antibody for lhr at RT or overnight at 4°C in dark. Cells were washed with PBS 3 times for 20 min each and mounted with vectashield mounting media with counterstaining with DAPI. The coverslips were imaged using confocal microscopy.
  • the plasmid pCMV-XL5 and cMyc cDNA were purchased from Origene. Both 1 ⁇ g pCMV- XL5 and 1 ⁇ g cMyc cDNA were digested using 1U EcoRI (New England Biologies) and 1U Notl (New England Biologies) enzyme at 37°C water bath for 2 h. Digested DNA was performed for gel electrophoresis for confirmation and isolation of the DNA from agarose gel.
  • Digested cMyc insert was cloned into multiple cloning site of the pCMV-XL5 vector.
  • DNA extracted from agarose gels was used for ligation using DNA Ligase enzyme and incubated at 16°C for overnight.
  • Ligation mixture was used for transforming competent E.coli DH 5a cells.Transformed DH 5a cells were plated onto LB amp plates and incubated at 37°C for overnight. After incubation, positive colonies were picked and plated into 5 ml LB broth medium. Incubation was performed at 37°C shaking incubator for overnight. Plasmid DNA was isolated from LB culture by Qiagen Mini prep. Restriction digestion using EcoRI and Notl was performed for all the isolated DNA.
  • the E.coli with plasmid containing gene of interest was inoculated into 200 ml LB medium and incubated for overnight at 37°C in shaking incubator. Isolated endofree plasmid from LB culture by Qiagen Midiprep. The isolated plasmid was used for transfecting human mammary epithelial cells.
  • the plasmid pCMV-BFP was purchased from Origene.
  • hTERT gene was amplified from genomic DNA of normal epithelial cells using specific primers. Both 1 ⁇ g pCMV-BFP and 1 ⁇ g hTERT PCR product was digested using 1U Hind III (New England Biologies) and 1U Not I (New England Biologies) enzyme at 37°C water bath for 2 h. Digested DNA was run on gel electrophoresis for confirmation and isolation of the DNA from agarose gel. Digested hTERT insert was cloned in the multiple cloning site of the pCMV-AC-mBFP vector.
  • DNA extracted from agarose gels was ligated using DNA Ligase enzyme and incubated at 16°C for overnight. Ligation mixture was used to transform competent E.coli DH5a cells. Transformed DH5a cells were plated onto LB amp plates and incubated at 37°C for overnight. After incubation, positive colonies were picked and plated into 5 ml LB broth medium. Incubation was performed at 37°C shaking incubator for overnight. Plasmid DNA was isolated from LB culture by Qiagen Mini prep kit. For confirmation of the clone, restriction digestion using Hind III and Not I was performed for all the isolated DNA.
  • E.coli with plasmid containing gene of interest was inoculated into 200 ml LB medium and incubated for overnight at 37°C in shaking incubator. Isolated endofree plasmid from LB culture by Qiagen Midiprep kit. The isolated plasmid was used for transfecting human mammary epithelial cells. c) E-Cad GFP plasmid
  • the plasmid pCMV E-Cadherin-GFP-neo was purchased from Origene.
  • E-Cadherin promoter was amplified from genomic DNA of normal epithelial cells.
  • Both 1 ⁇ g pCMV-E-Cadherin- GFP-neo and 1 ⁇ g E-Cadherin promoter DNA was digested using 1U Spel (New England Biologies) and 1U Bgl II (New England Biologies) enzyme at 37°C water bath for 2 h. Digested DNA was run on gel electrophoresis for confirmation and isolation of the DNA from agarose gel.
  • Digested E-Cadherin promoter insert was cloned upstream of the E-Cadherin gene of the pCMV-CDHl-GFP vector.
  • DNA extracted from agarose gels was used for ligation using DNA Ligase enzyme and incubated at 16°C for overnight.
  • Ligation mixture was used to transform competent E.coli DH 5a cells.
  • Transformed DH 5a cells were plated onto LB amp plates and incubated at 37°C for overnight. After incubation, positive colonies were picked and plated into 5 ml LB broth medium. Incubation was performed at 37°C shaking incubator for overnight. Plasmid DNA was isolated from LB culture by Qiagen Mini prep kit.
  • the plasmid pCMV tomato-neo was purchased from Origene.
  • cMet was amplified from pCRXL TOPO cMet plasmid using specific primers. Both 1 ⁇ g pCMV-tomato-neo and 1 ⁇ g PCR product of cMet were digested using 1U Nhe I (New England Biologies) and 1U Sac I (New England Biologies) enzyme at 37°C water bath for 2 h. Digested DNA was run on gel electrophoresis for confirmation and isolation of the DNA from agarose gel. Digested cMet insert was cloned into multiple cloning site of the pCMV-tomato-neo vector.
  • DNA extracted from agarose gels was ligated using DNA Ligase enzyme and incubated at 16°C for overnight. Ligation mixture was used to transform competent E.coli DH5a cells. Transformed DH 5a cells were plated onto LB kanamycin agar plates and incubated at 37°C for overnight.
  • Plasmid DNA was isolated from LB culture by Qiagen Mini prep kit. For confirmation of the clone, restriction digestion using Nhe I and Sac I was performed. The E.coli with plasmid containing gene of interest was inoculated into 200 ml LB medium and incubated for overnight at 37°C in shaking incubator. Isolated endofree plasmid from LB culture by Qiagen Midiprep. The isolated plasmid was used for transfecting cMyc + Ecad cells.
  • DMEM-F12 (1 :1) + 4% FBS + Antibiotics + Glutamax + EGF + Insulin + Hydrocortisone + N2. Cells were 70-80% confluent at the time of transfection. On the day of transfection, complete medium was removed 2 hrs before transfection and DMEM-F12 was added.
  • DNA & Fugene HD complex (Total volume of complex; 500 ⁇ 1 for a 35mm culture dish) was prepared with different concentrations of each plasmid in DMEM-F12 media without serum and antibiotics Different concentrations of DNA were used to transfect e.g., 0.01-0.5 ⁇ g c-Myc plasmid, 0.5 - 2.5 ⁇ g of hTERT-BFP, 0.5 - 2.5 ⁇ g Ecad-GFP, and 0.5 - 2.5 ⁇ g of cMet-tomato. DNA was added to the Fugene HD and incubated for 10 min at room temperature. Transfections were performed in duplicate. 250 ⁇ 1 of the complex was added and incubated for lhr @ 37°C in a C02 incubator.
  • Stable transfectant cMyc, cMyc + Ecad and cMyc + Ecad + cMet cells were regularly cultured in media containing Knockout DMEM, 15% FBS, 5% condition media, 20 ng/ml bFGF at 37°C/5%C02 incubator.
  • Viability assay was carried out using WST cell proliferation reagent (Takara, Cat # MK 400) as per the supplier's instructions. Normal HMEC cells and stable transfectant lines were seeded in triplicate in 96 well plates at a density of typically 5000 cells/well in culture medium and allowed to attach for 24 h at 37C/5%C02 incubator. After 24 hrs of attachment, test compounds were added and incubated for 3 to 6 days. 20 ⁇ of WST reagent was added to each well and incubated for 3 h at 37°C in 5% C02 incubator. The plate was shaken gently before reading for homogenous distribution of the colour. The absorbance was read using a microplate reader at 450 nm and 630 nm.
  • HMECs and transfected cell lines were tested for senescence using beta galactosidase chromogenic assay.
  • Cells were seeded on sterile coverslips at 5000 cells/well and allowed to attach for 24hrs. Fixation solution 4% paraformaldehyde was added to the cells & incubated for lOmin at room temp and then washed twice with PBS. Staining solution (K4 [Fe (CN) 6] 3H2 O and K3 [Fe (CN) 6]) was added to the cells and incubated at 37°C overnight in a humidifier in dark. After incubation, blue color can be seen visually. The staining solution was washed off, rinsed with PBS and then methanol. The cover slips were kept for drying and then viewed under phase microscope.
  • HMECs early passage monolayer HMECs and single, double and triple transfected cells were detached and plated in serum free media [DMEM-F12 (1: 1)] containing EGF, bFGF, B27 and N2 as supplements. Cells at 1-2x105 cells were plated in a 6 cm non-adherent culture dish and incubated for 3-7 days. Spheres were visible within 48hrs in triple transfected cells. Approximately 100-150 ⁇ size of spheres were formed by 5-7 days and were ready for passaging or drug treatment. The spheres were collected into 15ml falcon centrifuge tube, spun at lOOg for 5 min, followed by a PBS wash.
  • the pellet was resuspended in 0.5ml of Accutase and incubated in a shaking water bath at 37°C for 10-15min for sphere dissociation.
  • the pellet was triturated with a pi 000 pipette gently then spun down at 200g for 5min and the supernatant was discarded.
  • the pellet was resuspend in 0.5ml of serum free media. Cell were counted and plated as needed for second generation of spheres.
  • RNA Isolation Six-well plates were coated with 1 ml of 1% agarose as base agar. A 1 :1 mixture of 0.8% agarose at 40°C was prepared with warm 2X DMEM/F12, 20% FBS and 30,000 cells. 5,000 cells per well were plated in 6-well plates. After agarose solidified, 1 ml of IX DMEM/F12, 10% FBS containing media was added on top. Cells were cultured in soft agar medium for 30 - 40 days with media change twice a week. The number of colonies formed were counted visually. RNA Isolation
  • Reverse transcription master mix was prepared as below,
  • Fig. 1 it is a Representative phase contrast microscopy image of normal Human Mammary Epithelial cells (HMECs, Left panel) and normal human mammary fibroblasts (Right panel) grown in two dimensional culture at passage number 2. Objective magnification was 10X.
  • Normal Human Mammary Epithelial cells (HMECs) showed a typical cuboidal morphology with a small nucleus as seen in the left panel of Fig. 1. Very few vacuoles were observed indicating healthy growth of isolated cells that grew in close apposition. Cells from the fibroblast culture showed mostly flattened, more elongated and dispersed cells with no consistent shape (Right panel).
  • HMECs and fibroblast cells were characterized for the expression of epithelial and mesenchymal markers by the use of immunofluorescent antibodies and PCR (Prat A et al, 2013; Breast Cancer Res Treat; 142 (2): 237-55). Specific markers used for PCR included Mucin 1 and Desmoglein 2 (epithelial markers), and Slug, Snail, Twist 1, and Fibronectin (mesenchymal markers or fibroblast markers). Normal mammary epithelial and fibroblast cells at passage 2 were used for this characterization.
  • FIG. 2 it is an image representing expression of epithelial and mesenchymal markers in the isolated human mammary epithelial and fibroblast cells determined by PCR.
  • PCR products denoting expression of the genes Mucin 1 (171 bp, Lanes 1,2), Desmoglein 2 (278 bp, Lanes 3,4), Slug (181 bp, Lanes 6,7), Snail (248 bp, Lanes 8,9), Twist 1 (200 bp, Lanes 11,12), and Fibronectin (382 bp, Lanes 13,14) are shown.
  • GAPDH 115 bp, Lane 15
  • Lanes 5 and 10 represent the DNA ladder used to determine the size of the PCR products.
  • the letter ⁇ ' denotes epithelial cells and 'F' denotes fibroblasts as the source of the template.
  • Gene expression as determined by PCR (Fig. 2) showed that HMECs had a high expression of the epithelial markers Mucin 1 and Desmoglein 2. In contrast, normal human fibroblast cells did not have significant expression of these epithelial markers.
  • Fibroblasts isolated from the same human mammary tissue showed high expression of Slug, Snail, Twist 1, and Fibronectin mesenchymal markers whose expression was absent in the HMECs.
  • FIG. 3 they represent immunofluorescence images of HMECs. Representative images are at passage 2 showing staining for epithelial markers EpCAM (Panel A) and Cytokeratin 8/18 (CK8/18, Panel B). The cells do not have any detectable staining for the mesenchymal marker Vimentin (Panel C). All cells were also stained for DAPI, a nuclear marker, to visualize the number of cells and nuclear vs. cytosolic localization. Objective magnification was 60X. The epithelial nature of the cells isolated from normal breast epithelium was confirmed by immunofluorescence staining for antibodies to specific epithelial markers.
  • Epithelial cells from passage 2 were stained for epithelial markers EpCAM and Cytokeratin 8/18, and mesenchymal marker Vimentin. Good staining for both epithelial markers was observed in HMECs (Fig. 3; Panels A and B), while the expression of the mesenchymal marker Vimentin was below the detection level (Panel C). More than 90% of the cells in culture were positive for epithelial markers pointing to a purified population of epithelial cells.
  • FIG. 4 they represent immunofluorescence staining of normal human mammary fibroblast cells. Representative images are at passage 2 demonstrating lack of staining with the epithelial marker EpCAM (Panel A). Cells stained for the mesenchymal markers, a-Smooth Muscle Actin (a-SMA, Panel B) and Vimentin (Panel C) showed positive staining for both. All cells were also stained for DAPI, a nuclear marker, to visualize the number of cells and localize the nuclear vs cytosolic staining. Objective magnification was 60X. Fibroblast cells isolated from the normal breast tissue were also stained for the presence or absence of epithelial and mesenchymal markers by immunofluorescence.
  • EpCAM epithelial marker
  • Fibroblast cells from passage 2 did not stain for the epithelial marker EpCAM ( Figure 4, Panel A) but showed positive staining for the mesenchymal markers a-Smooth Muscle Actin (a-SMA, Panel B) and Vimentin (Panel C). Most of the cells (more than 90%) showed positive staining for the presence of fibroblast cells, suggesting that the culture methods produced a pure population of fibroblast cells.
  • HMECs were transfected with a plasmid designed to over-express c-myc (Drissi et al, 2001 ; J Biol Chem; 276 (32): 29994-30001) or hTERT (telomerase) genes. Over- expression of these genes may be used to immortalize the epithelial cells, extending their life span to beyond that of the primary cells.
  • Transfected cells were slowly weaned off the selection antibiotic (neomycin) in a stepwise manner over multiple passages, and allowed to grow in antibiotic free medium after passage 6. These cells, henceforth called singly transfected cells, showed epithelial characteristics such as cuboidal morphology with little vacuolization in phase contrast microscopy, c-myc transformed cells were grown for over 10 passages without significant loss of cell proliferation and viability unlike the untransfected HMECs which did not grow beyond passage 6. c-myc transfected cells from passage 10 were used for characterization for the expression of epithelial and mesenchymal markers using both PCR and immunofluorescence.
  • Fig. 5 it is a graphic representation of expression of epithelial and mesenchymal markers in c-myc immortalized stable cell line as determined by Quantitative Real-Time PCR.
  • Epithelial markers used were Mucin 1 and Desmoglein 2, while the mesenchymal markers used were Snail and Fibronectin.
  • the open bars represent HMECs at passage 3, and the filled bars represent passage 10 of HMECs transfected with c-myc. Bars denote average and SD of the assay done in triplicate.
  • Results of quantitative real-time PCR (Fig. 5) showed little change in the expression levels of the epithelial markers (Mucin 1 and Desmoglein 2) compared to HMECs.
  • Some expression of mesenchymal markers (Snail and Fibronectin) was also seen compared to HMECs. These cells may represent an intermediate phenotype to epithelial and mesenchymal cells.
  • FIGS. 6 they represent immunofluorescence images of HMECs transfected with c-myc. Representative images are at passage 10 showing cells stained with EpCAM (Left panel) and Vimentin (Right panel). All cells were stained with DAPI to visualize the number of cells and localization of cytosolic staining. Objective magnification was 20X. HMECs transfected with c-myc were stained with fluorescent antibodies for markers of epithelial and mesenchymal cells. EpCAM was used as epithelial markers while Vimentin was used as mesenchymal marker, c-myc transfected cells showed intense positive staining for EpCAM (Left Panel).
  • the staining is seen all over the cells and is shown as bright even distribution in the image.
  • Cells stained for Vimentin did not show any detectable levels of positive staining (Panel B). Only the nucleus stained with DAPI can be observed.
  • the size of the bright spots are smaller than seen in the left panel. These bright spots on the right panel only represent the nucleus unlike the left panel that shows both nuclear and cytoplasmic staining.
  • Immortalized human mammary cells (c-myc transfected primary cells) were further transfected with a plasmid to over-express E-cadherin gene under the regulation of its own promoter. This was tagged with a Green Fluorescence Protein (GFP) gene serving as an inbuilt reporter. During the process of Epithelial to Mesenchymal transition, E-cadherin is downregulated and this can be followed by the reduced expression of GFP in a phenotypic screen.
  • GFP Green Fluorescence Protein
  • Fig. 7 it is a graphic representation of expression of epithelial and mesenchymal markers in HMECs transfected with c-myc and E-Cadherin-GFP, as determined by Quantitative Real-Time PCR.
  • Epithelial markers used were Mucin 1 and Desmoglein 2, while the mesenchymal markers used were Snail and Fibronectin.
  • the open bars represent HMECs at passage 3
  • filled bars represent HMECs transfected with c-Myc and the grey shaded bars represent double transfected cells. Both the c-myc and double transfected cells were from passage 10. Bars denote average and SD of the assay done in triplicate.
  • Stable doubly transfected (c-myc and E-cadherin-GFP) cells were selected over multiple passages and characterized by both PCR and immunofluorescence staining to determine the expression levels of epithelial (Mucin 1 and Desmoglein 2), and mesenchymal markers (Snail and Fibronectin) at passage 10.
  • the double transfected cells express both the epithelial and mesenchymal markers (Fig 7) suggesting that these cells may also represent an intermediate stage of the EMT process.
  • Both Mucin 1 and Desmoglein 2 showed only a small decrease in their expression levels compared to the HMECs. However, the expression levels of both mesenchymal markers was higher in double transfected cells compared to both the HMECs and the cells transfected with c-myc alone.
  • Fig. 8 they are representative immunofluorescence images of double transfected cells at passage 10. EpCAM (Panel A) was used as an epithelial marker and Vimentin (Panel B) was used as a mesenchymal marker. All cells were stained with DAPI to visualize the nucleus and hence the number of cells. Objective magnification was 20X. Double transfected cells were stained with fluorescent labelled antibodies for detecting the expression of epithelial (EpCAM) and mesenchymal (Vimentin) markers. The double transfected cells showed staining for both these markers. However, as shown in Fig. 8, EpCAM showed a very intense positive staining and was seen all over cells with an even distribution (panel A). Cells stained for Vimentin show a moderate signal that was not distributed throughout the cells but was seen in limited areas of the cell cytoplasm (panel B). The images show both the cytoplasmic staining with the antibodies and the nuclear staining with DAPI.
  • EpCAM EpCAM
  • Vimentin me
  • FIG. 9 it is a representative phase contrast microscopy image of HMECs triple transfected with c-Myc, E-Cadherin-GFP, and c-Met-tomato maintained in two dimensional culture at passage number 10.
  • Objective magnification is at 10X.
  • Cells isolated from breast epithelium and stably transfected with c-myc and E-Cadherin-GFP were subsequently transfected with a c-Met-tomato reporter plasmid to evaluate the induction of EMT.
  • antibiotic-selected cells were maintained in a culture medium that was optimized to support mesenchymal cell growth.
  • Fig. 10 it is a graphical representation of the expression of epithelial and mesenchymal markers in HMECs triple transfected with c-myc, E-Cadherin-GFP and c-Met- tomato, as determined by Quantitative Real-Time PCR.
  • Epithelial markers used were Mucin 1 and Desmoglein 2, while the mesenchymal markers used were Snail and Fibronectin.
  • the open bars represent HMECs at passage 3
  • filled bars represent HMECs transfected with c-myc alone and the grey shaded bars represent triple transfected cells. Both the c-myc and triple transfected cells were obtained from passage 10. Bars denote average and SD of the assay done in triplicate.
  • Fig. 10 Analysis for gene expression by quantitative real time PCR for epithelial and mesenchymal markers in the triple transfected cells, at passage 10, showed even higher expression of mesenchymal markers compared to either HMECs or c-myc immortalized cells (Fig. 10). Moreover, the expression levels of the epithelial markers was observed to be much lower in these cells, -29% in the case of Desmoglein 2 and -41% for Mucin 1 compared to HMECs, and about half that of single transfected cells. [0109] Referring to Fig. 11, it is an image showing immunofluorescence staining of HMECs triple transfected with c-Myc, E-Cadherin-GFP, and c-Met, at passage 10.
  • Fig. 12 it represents a fluorescence microscopy image of triple transfected HMECs representing the expression of red coloured tomato reporter gene (right panel). Phase contrast microscopy image of the cells is depicted in the left panel. Images are taken with 20X objective. Expression of the reporter protein tomato (red fluorescence) was detected in the triple transfected cells by immunofluorescence as shown in Fig. 12. In the right panel, the bright dots indicated by arrows, are groups of cells that show intense red fluorescence and are the ones expressing c-Met-tomato and they range between 30 to 50% of the cells in culture.
  • telomeres have a limited life-span mainly due to the lack of hTERT (human Telomerase Reverse Transcriptase) expression leading to progressive shortening of the telomeres. When the telomeres reach a critical length, the cells undergo senescence and ultimately die.
  • Fig. 13 they are representative images of ⁇ -galactosidase assay to determine senescence in the different cell types developed. HMECs at passage 6 (Panel A) show intense blue colour in groups of cells indicated by arrows.
  • C-myc (Panel B), C-myc and E-Cadherin-GFP (Panel C), and C-Myc, E-Cadherin-GFP, and C-Met-tomato (Panel D) transfected cells were negative for the ⁇ -galactosidase assay. All the three transfected cell types used in this assay were from passage 10. Objective magnification was 10X. HMECs transfected with c-myc proliferate for a much longer time compared to the primary epithelial cells. These transfected cells do not show senescence even after passage number 10. As shown in Fig.
  • the primary epithelial cells, at passage 6, used as positive control cells take up blue colour of the beta-galactosidase stain (depicted by darker colour in panel A) in the cytoplasm indicating their being senescent. More than 50% of the cells in culture show senescence at this passage. These cells do not proliferate further and eventually die in culture. Cells that have been transfected with c-myc overcome this crisis and continue to proliferate. Lack of colour and thereby absence of sensescence was observed for the c-myc single transfected (panel B), c-myc and E-Cadherin-GFP double transfected cells (panel C), and the triple transfected cells (panel D). None of the cells in the three transfected cultures showed blue colouration in the cytoplasm and therefore demonstrated lack of senescence at passage 10.
  • Fig. 14 it is a graphical representation of Real-Time quantitative PCR to determine the expression levels of hTERT.
  • HMECs at passage 3 were used in this assay while the three transfected cell lines were from passage 10.
  • Relative fluorescence units were normalized to HMECs set at 100%.
  • Graph denotes the average and SD of the expression levels from an assay done in triplicate.
  • expression of hTERT mRNA is also used as an indicator of cellular immortalization. Expression of this gene was determined by quantitative real time PCR.
  • cells transfected with c-myc showed high hTERT expression (Fig. 14).
  • the triple transfected cells had the highest expression levels of hTERT.
  • Cells transfected with c-myc, E-Cadherin-GFP, and c-Met-tomato gain the mesenchymal cell characteristic of anchorage independent growth in serum free medium and the ability to form colonies in soft agar
  • Fig. 15 are images representing sphere forming assay in non-adherent plates and serum-free culture conditions. 100,000 cells were seeded and allowed to form spheres for 7 days. HMECs (Panel A) failed to form spheres and remained dispersed and slowly died, while cells transfected with c-myc (Panel B), c-myc + E-Cadherin-GFP (Panel C), and with c-myc + E-Cadherin-GFP + c-met-tomato (Panel D) formed spheres, albeit at different rates and sizes. HMECs were at passage 3 while the other three cell lines were at passage 10.
  • the size and number of spheres was significantly higher in single (Panel B) and triple transfected cells (Panel D) compared to double transfected cells (Panel C).
  • the single and triple transfected cells started to form spheres by day 3 while the double transfected cells started to form small spheres as late as day 7.
  • the triple transfected cells were embedded in albumin and then in paraffin as a block. The block was sectioned and immunostained for ER, PR and Her2 markers and shown to be triple negative breast cancer.
  • Fig. 16 are images representing colony forming assay in soft agar. Cells were seeded and allowed to form colonies for 40 days. Primary epithelial cells (Panel A) failed to form colonies, while cells transfected with c-myc + E-Cadherin-GFP (Panel B), and with c-myc + E-Cadherin-GFP + c-met-tomato (Panel C) formed colonies of different sizes. Images were taken with 10X objective of phase contrast microscope. (Change images to passage 10. In EMT PCT folder). Colony formation in soft agar, a hallmark of cancer cells, was assessed for 20-40 days in the presence of serum. As shown in the Fig.
  • HMECs did not form any colonies as expected from literature and remained dispersed as single cells that did not survive past 20 days.
  • the single, double and triple transfected cells did have the ability to form colonies.
  • the colonies in the double transfected cells (Panel B) were significantly smaller than in the triple transfected cells (Panel C) at 30 days. It took 40 days for the double transfected cells to form any colonies of about ⁇ size compared to only 30 days for the triple transfected cells.
  • Fig. 17 it is a graphical representation of the number of colonies formed in soft agar by the different cell types, based on the size of the colonies enumerated on Day 40.
  • the graphs represent the average and SD from duplicate wells of a representative experiment.
  • Representative data of the colony formation assay using cells from passage 10 is shown in Fig. 17.
  • the double transfected cells do form a few colonies in soft agar, they are primarily below 50 ⁇ in diameter. Colonies that are more than ⁇ are present only in the triple transfected cells indicating the presence of many tumour initiating cells able to form independent colonies, renew themselves and proliferate in the hypoxic conditions of soft agar that mimic tumour environment.
  • the results from the mammosphere and colony formation assays suggest that the epithelial cells transfected with the three plasmids have attained the characteristics of mesenchymal cells and also indicate the presence of cancer stem cells. Moreover, the triple transfected cells formed multiple new colonies rapidly in soft agar that suggests their ability to metastasize and form new cancers compared to HMECs.
  • Triple transfected cells grown as 3D mammosphere cultures are enriched for cancer stem cells
  • Fig. 18 it represents a flow cytometric detection of cancer stem cells (CSCs) by CD44 and CD24 antibody staining.
  • HMECs Panel A
  • c-myc single transfected cells Panel B
  • triple transfected cells Panel C
  • Mesenchymal cells derived in this study have a high migratory potential and the migration is modulated by small molecules
  • FIG. 19 it is a graphical representation of migration potential of the different cell types as determined by wound healing assay.
  • the panels correspond to A) HMECs, B) HMECs transfected with c-Myc, C) HMECs transfected with c-Myc and E- Cadherin-GFP, and D) HMECs transfected with c-Myc, E-Cadherin-GFP, and c-Met-Tomato.
  • the percentage of open wound area was calculated based on the density of the cells present in the scratch, when compared to the 0 hour of HMECs which was set at 100%.
  • the graphs are average and SD of triplicate wells from a representative experiment of two independent experiments.
  • the increased ability of cells to migrate from their point of origin is a hallmark of metastatic cancer and also of mesenchymal cells.
  • a uniform scratch is made in a confluent area of cell growth and all the cells in that area are removed; this absence of cells represents a wound.
  • the migration potential is measured by the ability of neighbouring cells to migrate into the scratched area to fill in the wound. As shown in the Fig.
  • the area of the open wound remained much higher in the HMECs (designated A) compared to that in cells which were transfected with either c-myc alone (B), c-myc and E-Cadherin-GFP (C), or with c-myc, E-Cadherin-GFP and c-met-tomato (D).
  • the area of the open wound is the least in the triple transfected cells compared to either the singly or doubly transfected cells suggesting that the triple transfected cells have the highest migratory potential. Consistent with published literature, a gain of migratory phenotype is observed even for the c-myc single transfected cells.
  • this EMT model can be used for discovering and/or validating novel biomarkers, new drug candidates or repurposing of known drugs for use in treating cancer e.g. triple negative breast cancer singly or in combination with other drugs.
  • TScratch a novel and simple software tool for automated analysis of monolayer wound healing assays. Geback T, Schulz MM, Koumoutsakos P, Detmar M. Biotechniques. 2009; 46 (4):265-74. 16. The Soft Agar Colony Formation Assay. Borowicz, S., Van Scoyk, M., Avasarala, S., Karuppusamy Rathinam, M. K., Tauler, J., Bikkavilli, R. K., et al. . J. Vis. Exp. (92), (2014).
  • RNA isolation and reverse transcription protocol cells in culture By Dr. Richard Pattern, Tufts-New England Medical Centre, Boston.
  • CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Des modes de réalisation donnés à titre illustratif de la présente invention concernent des produits qui servent de modèles pour une transition épithélio-mésenchymateuse et des procédés et des utilisations associés. Le produit comprend une pluralité d'éléments constitutifs, la pluralité d'éléments constitutifs étant choisie à partir d'un ou de plusieurs des groupes suivants: une population de cellules épithéliales primaires; une population de cellules fibroblastiques primaires; une première lignée cellulaire stable immortalisée présentant un phénotype épithélial ou intermédiaire abritant une construction génétique immortalisante modifiée; une deuxième lignée cellulaire stable immortalisée présentant un phénotype épithélial ou intermédiaire abritant une construction génétique immortalisante modifiée et une construction de gène marqueur déterminable modifiée; une troisième lignée cellulaire stable immortalisée présentant un phénotype mésenchymateux ou de type mésenchymateux abritant une construction génétique immortalisante modifiée, une construction de gène marqueur déterminable modifiée et une construction génétique induisant une EMT modifiée; un agent de modulation d'EMT; et une population enrichie de cellules souches cancéreuses issues de la troisième lignée cellulaire stable immortalisée.
PCT/IB2015/059724 2014-12-18 2015-12-17 Établissement et utilisation d'une plateforme in vitro pour transition épithélio-mésenchymateuse (emt) WO2016098041A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2986CH2014 2014-12-18
IN2986/CHE/2014 2014-12-18

Publications (1)

Publication Number Publication Date
WO2016098041A1 true WO2016098041A1 (fr) 2016-06-23

Family

ID=55229762

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/059724 WO2016098041A1 (fr) 2014-12-18 2015-12-17 Établissement et utilisation d'une plateforme in vitro pour transition épithélio-mésenchymateuse (emt)

Country Status (1)

Country Link
WO (1) WO2016098041A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114317542A (zh) * 2021-09-30 2022-04-12 中国药科大学 一种诱导肿瘤细胞上皮间质转化药物的筛选探针及其制备方法和应用

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009051660A2 (fr) 2007-10-12 2009-04-23 The Board Of Trustees Of The Leland Stanford Junior University Composés permettant l'activation de la signalisation tgf-bêta
WO2009126310A2 (fr) * 2008-04-10 2009-10-15 Massachusetts Institute Of Technology Procédés d’identification et utilisation d’agents ciblant les cellules souches cancéreuses
US20100088775A1 (en) 2006-05-26 2010-04-08 Medvet Science Pty. Ltd. Methods of modulating epithelial-mesenchymal transition and mesenchymal-epithelial transition in cells and agents useful for the same
US20110033471A1 (en) 2005-09-13 2011-02-10 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
US20120156216A1 (en) 2009-03-02 2012-06-21 Youngman Oh Methods and Compositions for Treatment of Tumor Metastasis
US20120220546A1 (en) 2009-11-05 2012-08-30 Avila Zaragoza Matias Antonio Compostions designed for the inhibition and/or blocking of the epithelial/mesenchymal transition
EP2569335A2 (fr) 2010-05-14 2013-03-20 Orega Biotech Méthodes de traitement et/ou de prévention de troubles de prolifération cellulaire à l'aide d'antagonistes de il-17
US20130158087A1 (en) 2010-06-21 2013-06-20 Board Of Regents, The University Of Texas System Tg2 inhibitors and uses thereof
WO2013123588A1 (fr) 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Utilisation conjointe d'un inhibiteur de clusterine et d'un inhibiteur d'egfr pour traiter le cancer
WO2013131000A1 (fr) * 2012-03-01 2013-09-06 Whitehead Institute For Biomedical Research Des facteurs de transcription pour l'induction d'emt coopèrent avec sox9
WO2014139885A2 (fr) * 2013-03-14 2014-09-18 Galapagos Nv Cibles et composés moléculaires, et procédés pour les identifier, utiles dans le traitement de maladies associées à une transition épithélio-mésenchymateuse

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110033471A1 (en) 2005-09-13 2011-02-10 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
US20100088775A1 (en) 2006-05-26 2010-04-08 Medvet Science Pty. Ltd. Methods of modulating epithelial-mesenchymal transition and mesenchymal-epithelial transition in cells and agents useful for the same
WO2009051660A2 (fr) 2007-10-12 2009-04-23 The Board Of Trustees Of The Leland Stanford Junior University Composés permettant l'activation de la signalisation tgf-bêta
WO2009126310A2 (fr) * 2008-04-10 2009-10-15 Massachusetts Institute Of Technology Procédés d’identification et utilisation d’agents ciblant les cellules souches cancéreuses
US20120156216A1 (en) 2009-03-02 2012-06-21 Youngman Oh Methods and Compositions for Treatment of Tumor Metastasis
US20120220546A1 (en) 2009-11-05 2012-08-30 Avila Zaragoza Matias Antonio Compostions designed for the inhibition and/or blocking of the epithelial/mesenchymal transition
EP2569335A2 (fr) 2010-05-14 2013-03-20 Orega Biotech Méthodes de traitement et/ou de prévention de troubles de prolifération cellulaire à l'aide d'antagonistes de il-17
US20130158087A1 (en) 2010-06-21 2013-06-20 Board Of Regents, The University Of Texas System Tg2 inhibitors and uses thereof
WO2013123588A1 (fr) 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Utilisation conjointe d'un inhibiteur de clusterine et d'un inhibiteur d'egfr pour traiter le cancer
WO2013131000A1 (fr) * 2012-03-01 2013-09-06 Whitehead Institute For Biomedical Research Des facteurs de transcription pour l'induction d'emt coopèrent avec sox9
WO2014139885A2 (fr) * 2013-03-14 2014-09-18 Galapagos Nv Cibles et composés moléculaires, et procédés pour les identifier, utiles dans le traitement de maladies associées à une transition épithélio-mésenchymateuse

Non-Patent Citations (79)

* Cited by examiner, † Cited by third party
Title
"Cancer: Principles and Practice of Oncology", 2008, J. B. LIPPINCOTT COMPANY
"Current Protocols in Molecular Biology, Current Protocols ii, immunology, Current Protocols in Protein Science, and Current Protocols in Cell Biology", 2008, JOHN WILEY & SONS
"Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Christine M Fillmorel and Charlotte Kuperwasser", BREAST CANCER RESEARCH, vol. 10, 2008, pages R25
"Monoclonal antibodies: a practical approach", 2000, OXFORD UNIVERSITY PRESS
"TRIZOL RNA Isolation Protocol W.M. Keck Foundation Biotechnology Microarray", RESOURCE LABORATORY AT YALE UNIVERSITY
ANDREA SADLONOVA; SHIBANI MUKHERJEE; DAMON B. BOWE; F SANDRA R. GAULT; NICOLE A. DUMAS; $ BRIAN A. VAN TINE; NATALYA FROLOVA; GRIE, HUMAN BREAST FIBROBLASTS INHIBIT GROWTH OF THE MCF10AT XENOGRAFT MODEL OF PROLIFERATIVE BREAST DISEASE
ARANTZAZU ZUBELDIA-PLAZAOLAL; ELISABET AMETLLER; MARIO MANCINO; MIQUEL PRATS DE PUIG; ANNA LOPEZ-PLANAL; FLAVIA GUZMAN; LAIA VINYA, COMPARISON OF METHODS FOR THE ISOLATION OF HUMAN BREAST EPITHELIAL AND MYOEPITHELIAL CELLS
ARANTZAZU ZUBELDIA-PLAZAOLAL; ELISABET AMETLLER; MARIO MANCINOL; MIQUEL PRATS DE PUIG; ANNA LOPEZ-PLANAL; FLAVIA GUZMAN; LAIA VINY, COMPARISON OF METHODS FOR THE ISOLATION OF HUMAN BREAST EPITHELIAL AND MYOEPITHELIAL CELLS
BOROWICZ, S.; VAN SCOYK, M.; AVASARALA, S.; KARUPPUSAMY RATHINAM, M. K.; TAULER, J.; BIKKAVILLI, R. K. ET AL.: "The Soft Agar Colony Formation Assay", J. VIS. EXP., 2014
BURNS, R.: "Immunochemical Protocols (Methods in Molecular Biology", 2005, HUMANA PRESS
CARMICHAEL, J. ET AL., CANCER RES., vol. 47, 1987, pages 936 - 942
CAROL SHERIDANL; HIROMITSU KISHIMOTOL ET AL.: "CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis", BREAST CANCER RESEARCH, vol. 8, 2006, pages R59
CHRISTOFORI G, NATURE, vol. 441, 2006, pages 444 - 450
CHRISTOFORI G: "New signals from the invasive front", NATURE, vol. 441, 2006, pages 444 - 450
COOK, J. A.; MITCHELL, J. B.: "Premix WST-1 Cell Proliferation Assay System {1", ANAL. BIOCHEM, vol. 179, 1989, pages 1 - 7
CORY, A. H. ET AL., CANCER COMMUN., vol. 3, 1991, pages 207 - 212
DIMRI G ET AL., BREAST CANCER RES, vol. 7, no. 4, 2005, pages 171 - 9
DIMRI G; BAND H; BAND V.: "Mammary epithelial cell transformation: insights from cell culture and mouse models", BREAST CANCER RES., vol. 7, no. 4, 3 June 2005 (2005-06-03), pages 171 - 9
DRISSI ET AL., J BIOL CHEM, vol. 276, no. 32, 2001, pages 29994 - 30001
DRISSI R ET AL., J BIOL CHEM, vol. 276, no. 32, 2001, pages 29994 - 30001
DRISSI R; ZINDY F; ROUSSEL MF; CLEVELAND JL.: "c-Myc-mediated regulation of telomerase activity is disabled in immortalized cells", J BIOL CHEM., vol. 276, no. 32, 10 August 2001 (2001-08-10), pages 29994 - 30001
F BORELLINI; T OKA, GROWTH CONTROL AND DIFFERENTIATION IN MAMMARY EPITHELIAL CELLS
FILLMORE; KUPERWASSER, BREAST CANCER RES, vol. 10, 2008, pages R25
FILLMORE; KUPERWASSER, BREAST CANCER RESEARCH, vol. 10, 2008, pages R25
FLORENCE DEBACQ-CHAINIAUX; JORGE D ERUSALIMSKY; JUDITH CAMPISI; OLIVIER TOUSSAINT: "Protocols to detect senescence-associated beta-galactosidase (SA-? gal) activity, a biomarker of senescent cells in culture and in vivo", NATURE PROTOCOLS, vol. 4, 2009, pages 1798 - 1806
FRESHNEY, R. I.: "Culture of Animal Cells, A Manual of Basic Technique", 2005, JOHN WILEY & SONS
GABRIELA DONTU; WISSAM M. ABDALLAH; JESSICA M. FOLEY; KYLE W. JACKSON; MICHAEL F. CLARKE; MARI J. KAWAMURA; MAX S. WICHA: "In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells", GENES AND DEV., 2003
GAULE PB ET AL., EXPERT OPIN THER TARGETS, vol. 18, no. 9, 2014, pages 999 - 1009
GAULE PB; CROWN J; O'DONOVAN N; DUFFY MJ.: "cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?", EXPERT OPIN THER TARGETS, vol. 18, no. 9, September 2014 (2014-09-01), pages 999 - 1009
GEBACK T; SCHULZ MM; KOUMOUTSAKOS P; DETMAR M.: "TScratch: a novel and simple software tool for automated analysis of monolayer wound healing assays", BIOTECHNIQUES, vol. 46, no. 4, 2009, pages 265 - 74
GUPTA PB ET AL., CELL, vol. 138, no. 4, 2005, pages 645 - 59
GUPTA PB; MANI S; YANG J; HARTWELL K; WEINBERG RA: "The evolving portrait of cancer metastasis", COLD SPRING HARB SYMP QUANT BIOL., vol. 70, 2005, pages 291 - 7
HANAHAN D ET AL., CELL, vol. 144, 2011, pages 646 - 674
HANAHAN D; WEINBERG RA: "Hallmarks of cancer: the next generation", CELL, vol. 144, 2011, pages 646 - 674
HARLOW, E.; LANE, D.: "Antibodies—A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY PRESS
HOOK, B.; SCHAGAT, T.: "Manual of Style", 2007, PROMEGA CORPORATION, article "Reverse Transfection Using FuGENE@ 6 and FuGENE@ HD."
HOOK, B.; SCHAGAT, T.: "Scientific Style and Format", 2006, article "Reverse Transfection Using FuGENE@ 6 and FuGENE@ HD."
KATZ R.: "Biomarkers and Surrogate Markers: An FDA Perspective", NEURORX, vol. 1, 2004, pages 189 - 195
KATZ, NEURORX., vol. 1, 2004, pages 189 - 195
KIM ET AL., EXPERIMENTAL & MOLECULAR MEDICINE, vol. 47, 2015, pages E137
KIM ET AL.: "Activation of KRAS promotes the mesenchymal features of basal-type breast cancer", EXPERIMENTAL & MOLECULAR MEDICINE, vol. 47, 2015, pages E137
KWIATKOWSKA-BOROWCZYK ET AL., CONTEMP ONCOL (POZN, vol. 19, 2015, pages A52 - A59
KWIATKOWSKA-BOROWCZYK ET AL.: "Immunotargeting of cancer stem cells", CONTEMP ONCOL (POZN, vol. 19, 2015, pages A52 - A59
LEE JM ET AL., J CELL BIOL, vol. 172, no. 7, 2006, pages 973 - 81
LEE JM; DEDHAR S; KALLURI R; THOMPSON EW.: "The epithelial-mesenchymal transition: new insights in signaling, development, and disease", J CELL BIOL., vol. 172, no. 7, 27 December 2005 (2005-12-27), pages 973 - 81
LI ET AL., J BIOMOL SCREEN, 2011
LI ET AL., J BIOMOL SCREEN, vol. 16, 2011, pages 141
LI ET AL.: "3D Models of Epithelial-Mesenchymal Transition in Breast Cancer Metastasis: High-Throughput Screening Assay Development, Validation, and Pilot Screen", J BIOMOL SCREEN, vol. 16, 2011, pages 141
MARK A. LABARGE; JAMES C. GARBE; MARTHA R. STAMPFER, PROCESSING OF HUMAN REDUCTION MAMMOPLASTY AND MASTECTOMY TISSUES FOR CELL CULTURE
MARTHA R. STAMPFERL; PAUL YASWENL; JOYCE TAYLOR-PAPADIMITRIOU, CULTURE OF HUMAN MAMMARY EPITHELIAL CELLS
MARTIN JECHLINGER ET AL: "Expression profiling of epithelial plasticity in tumor progression", ONCOGENE, vol. 22, no. 46, 16 October 2003 (2003-10-16), GB, pages 7155 - 7169, XP055264639, ISSN: 0950-9232, DOI: 10.1038/sj.onc.1206887 *
MICHEAL R GREEN; JOSEPH SAMBROOK: "Molecular Cloning, A Laboratory Manual", 2012
MINUTI G; LANDI L.: "MET deregulation in breast cancer", ANN TRANSL MED., vol. 3, no. 13, August 2015 (2015-08-01), pages 181
MINUTI; LANDI, ANN TRANSL MED., vol. 3, 2015, pages 181
MOSMANN, T., J. IMMUNOL. METHODS, vol. 65, 1983, pages 55 - 63
NAO R. KOBAYASHIL ET AL.: "Modelling Disrupted-in-Schizophrenia 1 loss of function in human neural progenitor cells: tools for molecular studies of human neurodevelopment and neuropsychiatric disorders", MOL PSYCHIATRY, vol. 15, no. 7, July 2010 (2010-07-01), pages 672 - 5
NISHIKATA T ET AL.: "Primary culture of breast cells: a model system for epithelial.mesenchymal transition and cancer stem cells", ANTICANCER RESEARCH, vol. 33, 1 December 2013 (2013-12-01), pages 2867 - 2874, XP055264081, Retrieved from the Internet <URL:http://ar.iiarjournals.org/content/33/7/2867.full.pdf> [retrieved on 20160411] *
ORGAN SL ET AL., THER ADV MED ONCOL, vol. 3, no. 1, 2011, pages S7 - S19
ORGAN SL; TSAO MS.: "An overview of the c-MET signaling pathway", THER ADV MED ONCOL., vol. 3, no. 1, November 2011 (2011-11-01), pages S7 - S19
OUYANG G ET AL., CELL MOL LIFE SCI, vol. 67, no. 15, 2010, pages 2605 - 18
OUYANG G; WANG Z; FANG X; LIU J; YANG CJ.: "Molecular signaling of the epithelial to mesenchymal transition in generating and maintaining cancer stem cells", CELL MOL LIFE SCI., vol. 67, no. 15, August 2010 (2010-08-01), pages 2605 - 18
PIYUSH B. GUPTA ET AL: "Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening", CELL, vol. 138, no. 4, 1 August 2009 (2009-08-01), pages 645 - 659, XP055001903, ISSN: 0092-8674, DOI: 10.1016/j.cell.2009.06.034 *
PRAT A ET AL., BREAST CANCER RES TREAT, vol. 142, no. 2, 2013, pages 237 - 55
PRAT A; KARGINOVA O; PARKER JS; FAN C; HE X; BIXBY L; HARRELL JC; ROMAN E; ADAMO B; TROESTER M: "Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes", BREAST CANCER RES TREAT., vol. 142, no. 2, November 2013 (2013-11-01), pages 237 - 55
PRITHI RAJAN; RONALD D. G.: "Multiple Routes to Astrocytic Differentiation in the CNS", NATIONAL INSTITUTES OF HEALTH
RICHARD PATTERN, RNA ISOLATION AND REVERSE TRANSCRIPTION PROTOCOL: CELLS IN CULTURE
ROEHM, N. W. ET AL., J. IMMUNOL. METHODS, vol. 142, 1991, pages 257 - 265
SAMBROOK; RUSSELL; SAMBROOK: "Molecular Cloning: A Laboratory Manual", 2001, COLD SPRING HARBOR LABORATORY PRESS
SCUDIERO, D. A. ET AL., CANCER RES., vol. 48, 1988, pages 4827 - 4833
SHERIDAN ET AL., BREAST CANCER RESEARCH, vol. 8, 2006, pages R59
SLATER, T. F.; SAWYER, B.; STRAIT, U., BIOCHIM. BIOPHYS. ACTA, vol. 77, 1963, pages 383 - 393
STAMPFER M ET AL., IN VITRO, vol. 16, no. 5, 1980, pages 415 - 25
STAMPFER M; HALLOWES RC; HACKETT AJ.: "Growth of normal human mammary cells in culture", IN VITRO, vol. 16, no. 5, May 1980 (1980-05-01), pages 415 - 25
VISTICA, D. T. ET AL., CANCER RES., vol. 51, 1991, pages 2515 - 2520
WANG CC; BAJIKAR SS; JAMAL L; ATKINS KA; JANES KA: "Immunofluorescence on cells in suspension", NAT CELL BIOL, vol. 16, 2014, pages 345 - 56
WEINBERG, R A ET AL.: "The Biology of Cancer", 2006, GARLAND SCIENCE
WEISLOW, O. S. ET AL., J. NATL. CANCER. INST., vol. 81, 1989, pages 577 - 586
YAUSCH ET AL., CLIN CANCER RES, vol. 11, 2005, pages 8686
YAUSCH ET AL.: "Epithelial versus mesenchymal phenotype determines invitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients", CLIN CANCER RES., vol. 11, 2005, pages 8686

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114317542A (zh) * 2021-09-30 2022-04-12 中国药科大学 一种诱导肿瘤细胞上皮间质转化药物的筛选探针及其制备方法和应用
CN114317542B (zh) * 2021-09-30 2024-08-23 中国药科大学 一种诱导肿瘤细胞上皮间质转化药物的筛选探针及其制备方法和应用

Similar Documents

Publication Publication Date Title
Unterleuthner et al. Cancer-associated fibroblast-derived WNT2 increases tumor angiogenesis in colon cancer
Britschgi et al. The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk with ERα
Lioni et al. Dysregulation of claudin-7 leads to loss of E-cadherin expression and the increased invasion of esophageal squamous cell carcinoma cells
Luca et al. Impact of the 3D microenvironment on phenotype, gene expression, and EGFR inhibition of colorectal cancer cell lines
Rodilla et al. Luminal progenitors restrict their lineage potential during mammary gland development
He et al. Isolation and characterization of cancer stem cells from high-grade serous ovarian carcinomas
Yang et al. RAC1 activation mediates Twist1-induced cancer cell migration
Xu et al. The fibroblast Tiam1-osteopontin pathway modulates breast cancer invasion and metastasis
Kodet et al. Melanoma cells influence the differentiation pattern of human epidermal keratinocytes
Zeng et al. Stress-response protein RBM3 attenuates the stem-like properties of prostate cancer cells by interfering with CD44 variant splicing
Blanchette-Farra et al. Contribution of three-dimensional architecture and tumor-associated fibroblasts to hepcidin regulation in breast cancer
Park et al. Adipose-derived stem cells induced EMT-like changes in H358 lung cancer cells
Zhang et al. Numb and Numbl act to determine mammary myoepithelial cell fate, maintain epithelial identity, and support lactogenesis
Duss et al. An oestrogen-dependent model of breast cancer created by transformation of normal human mammary epithelial cells
Rosendahl et al. Conditionally immortalized human pancreatic stellate cell lines demonstrate enhanced proliferation and migration in response to IGF-I
Messai et al. Cytokeratin 18 expression pattern correlates with renal cell carcinoma progression: relationship with Snail
Maya-Mendoza et al. Cellular microenvironment controls the nuclear architecture of breast epithelia through β1-integrin
Worssam et al. Cellular mechanisms of oligoclonal vascular smooth muscle cell expansion in cardiovascular disease
D’Amato et al. Evidence for phenotypic plasticity in aggressive triple-negative breast cancer: human biology is recapitulated by a novel model system
Zhang et al. LY2109761, transforming growth factor β receptor type I and type II dual inhibitor, is a novel approach to suppress endothelial mesenchymal transformation in human corneal endothelial cells
Jiao et al. TGF-β signaling regulates SPOP expression and promotes prostate cancer cell stemness
Hou et al. Comparison of gene expression profiles in primary and immortalized human pterygium fibroblast cells
Uribe et al. Arid3b is essential for second heart field cell deployment and heart patterning
Myung et al. Expression of early growth response-1 in human gastric cancer and its relationship with tumor cell behaviors and prognosis
Jhingory et al. Novel insight into the function and regulation of αN-catenin by Snail2 during chick neural crest cell migration

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15828526

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15828526

Country of ref document: EP

Kind code of ref document: A1